ОСЛОЖНЕНИЯ ТАРГЕТНОЙ ТЕРАПИИ ПРИ ЛЕЧЕНИИ ПОЧЕЧНО- КЛЕТОЧНОГО РАКА С МЕТАСТАЗАМИ В КОСТЯХ И ЛИМФОУЗЛАХ

Аннотация

The article presents the results obtained during adjuvant targeted therapy in patients with locally advanced renal cell carcinoma with drugs belonging to the group of RANKL inhibitors and angiogenesis blockers. Complications of targeted therapy were studied in 46 patients with renal cell carcinoma who metastasized to bone in regional lymph nodes. The following side effects have been reported during treatment with axitinib and denosumab: weakness, increased blood pressure or exacerbation of hypertension, diarrhea, or hypothyroidism. Based on the results obtained, we recommend the use of acitinib and denosumab in patients with metastasis to the lymph nodes and bones of renal cancer, with particular emphasis on the prevention of complications in treatment.